ALVO
Alvotech
stockNASDAQ
alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.86 | 2026-11-06 | -13.99% | -0.766 |
| 1M | 5.38 | 2026-10-13 | -22.30% | 1.215 |
| 3M | 4.09 | 2026-08-13 | +2.20% | 0.968 |
| 6M | 3.67 | 2026-05-13 | +13.90% | 0.560 |
| 1Y | 5.52 | 2025-11-13 | -24.27% | 0.825 |
| 2Y | 11.93 | 2024-11-13 | -64.96% | — |
| 5Y | 11.19 | 2022-06-16 | -62.65% | 0.577 |
Alvotech (NASDAQ:ALVO) stock price today is $4.18, and today's volume is 2,091,332. ALVO is down 10.493% today. The 30 day average volume is 1.01M. ALVO market cap is $1.49B with 356.82M shares outstanding.